Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Janssen-Cilag Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (136)
Cancellation by sponsor (43)
Australian Public Assessment Report (AusPAR) (34)
Prescription medicine registration (22)
Designation or determination (6)
Prescription medicine evaluation (6)
Prescription medicine decision summary (5)

Date

2024 (20)
2023 (17)
2022 (13)
2021 (15)
2020 (25)
2019 (7)
2018 (9)
2017 (19)
2016 (19)
2015 (7)
2014 (12)
2013 (5)
2012 (5)
2011 (4)
2010 (19)
2009 (6)
2008 (2)
2007 (5)
2006 (3)
2005 (5)
2004 (3)
2003 (6)
2002 (2)
2000 (9)
1998 (10)
1996 (1)
1994 (1)
1993 (3)

Results for "[search-keyword]"

Search

Sponsor content

252 result(s) found, displaying 81 to 90

BOSENTAN ACTELION bosentan 62.5mg (as monohydrate) tablet bottle Cancelled under Section 30(1)(c) of the Act

29 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
BOSENTAN ACTELION bosentan 125mg (as monohydrate) tablet bottle Cancelled under Section 30(1)(c) of the Act

29 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
ERLYAND apalutamide 60 mg film-coated tablet bottle (299792)

5 July 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ERLYAND apalutamide 60 mg film-coated tablet bottle.
JANSSEN APALUTAMIDE apalutamide 60 mg film-coated tablet bottle (299791)

5 July 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for JANSSEN APALUTAMIDE apalutamide 60 mg film-coated tablet bottle.
JANSSEN DARATUMUMAB daratumumab 100 mg/5 mL concentrated solution for infusion vial Cancelled under Section 30(1)(c) of the Act

2 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
JANSSEN DARATUMUMAB daratumumab 400 mg/20 mL concentrated solution for infusion vial Cancelled under Section 30(1)(c) of the Act

2 June 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
TREVICTA paliperidone (as palmitate) 175 mg suspension for injection prefilled syringe Cancelled under Section 30(1)(c) of the Act

20 May 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
TREVICTA paliperidone (as palmitate) 263 mg suspension for injection prefilled syringe Cancelled under Section 30(1)(c) of the Act

20 May 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
TREVICTA paliperidone (as palmitate) 350 mg suspension for injection prefilled syringe Cancelled under Section 30(1)(c) of the Act

20 May 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd
TREVICTA paliperidone (as palmitate) 525 mg suspension for injection prefilled syringe Cancelled under Section 30(1)(c) of the Act

20 May 2020

Cancellation by sponsor

Requested by Janssen-Cilag Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.